continued until disease progression, unacceptable toxicity, or up to 12 months (combination therapy) or up to 24 months (monotherapy) Other indication: select patients with Merkel cell carcinoma (Accelerated Approval) May 19, 2025 antihemophilic factor (recombinant), PEGylated-aucl (Jivi) Bayer
Most of our patients were treated with liraglutide and dulaglutide (93%), which may not represent the situation in other regions in the world
Both compounds independently cause nausea, vomiting, diarrhea, and constipation - especially during dose increases
The severity of injuries now forming the basis of litigation demonstrates why plaintiffs allege manufacturers failed to provide adequate warnings about risks that extend well beyond temporary side effects
[55] This dysfunctional state limits the tissue's ability to safely store lipids and decreases the baseline activity of critical metabolic regulators like AMPK